Abstract: OBJECTIVE To evaluate the effectiveness, safety and economics of daptomycin in the treatment of complex skin and soft tissue infections(cSSTIs). METHODS Chinese and English literature database were searched, and relevant randomized controlled trials(RCTs) were included, meta-analysis and economics analysis based on the clinical cure rate and adverse reactions were conducted. RESULTS Six RCTs were included, involving 820 patients. The results of meta-analysis showed that, there was no significant difference in the clinical cure rate between the daptomycin group and the vancomycin groupRR=1.01, 95% CI(0.94, 1.08), P=0.88, and also in the daptomycin group and teicoplanin groupRR=1.02, 95%CI(0.90, 1.15), P=0.77. The incidence of adverse reactions was similar in the daptomycin group compared with vancomycin and teicoplanin group. The results of cost-minimization analysis showed that the cost of the daptomycin group was 9 128.25 yuan, the cost of the vancomycin group was 4 138.60 yuan, and the teicoplanin group was 4 429.34 yuan. Meanwhile, the sensitivity analysis showed that the results were stable. CONCLUSION For patients with cSSTIs, daptomycin is not economical compared to vancomycin and teicoplanin. However, with the changes in medical insurance policies, the economic characteristics of daptomycin may be also changed and further researches are needed.